The results indicate that HSYA treatment effectively reduces sepsis-induced apoptosis of peripheral blood CD4+ T lymphocytes, and this protection may be associated with its inhibitory action on inflammatory response and its modulation of pro-/anti-apoptotic protein expression, including Cytc, Bax, Bcl-2, cleaved caspase-9, and cleaved caspase-3. The gene discussed is BCL2; the disease is Sepsis.